|Jmol-3D images||Image 1|
|Molar mass||777.87 g mol−1|
|Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa)|
|(what is: / ?)|
UK-432,097 is a drug developed by Pfizer for the treatment of chronic obstructive pulmonary disease, which acts as a potent and selective agonist of the adenosine A2A receptor. It was discontinued from clinical trials following poor efficacy results, but its high selectivity has made it useful for detailed mapping of the internal structure of the A2A receptor.
- Russo, Cristina; Arcidiacono, Giuseppe; Polosa, Riccardo (2006). "Adenosine receptors: promising targets for the development of novel therapeutics and diagnostics for asthma". Fundamental and Clinical Pharmacology 20 (1): 9–19. doi:10.1111/j.1472-8206.2005.00388.x. PMID 16448391.
- Safety And Efficacy Of UK-432,097 In Chronic Obstructive Pulmonary Disease. ClinicalTrials.gov
- Xu F, Wu H, Katritch V, Han GW, Jacobson KA, Gao ZG, Cherezov V, Stevens RC (March 2011). "Structure of an Agonist-Bound Human A2A Adenosine Receptor". Science 332 (6027): 322–7. doi:10.1126/science.1202793. PMC 3086811. PMID 21393508.
|This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.|
|This article about an organic compound is a stub. You can help Wikipedia by expanding it.|